{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-068301","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2022-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.204790+00:00","generated_at":"2026-06-25T04:26:09.440771+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HOOKIPA Phase 1 HB-200 shows 80% disease control with alternating 2-vector; Phase 2 initiated","bullets":["Alternating 2-vector HB-202/HB-201 achieved 80% disease control rate vs historical 35-40% for pembrolizumab.","56% of alternating 2-vector patients had target lesion shrinkage vs 38% for single-vector HB-201.","32% on alternating 2-vector had tumor-specific T cells >5% of circulating pool vs 7% on HB-201.","HB-200 well tolerated; only 8.8% grade ≥3 treatment-related side effects, mostly flu-like symptoms.","Phase 2 plans include combos with pembrolizumab; initial results expected H2 2022, randomized trial H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-068301","json":"https://secwatch.observer/filing/0001104659-22-068301.json","markdown":"https://secwatch.observer/filing/0001104659-22-068301.md","text":"https://secwatch.observer/filing/0001104659-22-068301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922068301/0001104659-22-068301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922068301/tm2217741d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T04:26:09.440771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}